Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial

Sarah A. Taylor, John Crowley, F. Stephen Vogel, Jeannette J. Townsend, Harmon J. Eyre, Kurt A. Jaeckle, Harry E. Hynes, Jerry T. Guy

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.

Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalInvestigational New Drugs
Volume9
Issue number2
DOIs
StatePublished - May 1991

Keywords

  • central nervous system tumors
  • fludarabine phosphate
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial'. Together they form a unique fingerprint.

Cite this